Short name: PLLGd-DTPA, generic name: (Gd-DTPA)n-polylysine, chemical compound: Gd-DTPA poly(L-lysine-Gd-diethylenetriamine-N,N,N',N'',N''-pentaacetic acid), central moiety: Gd2+, relaxivity: r1=13.1, B0=0.23T
A polymeric MRI contrast agent under development (preclin., Bayer Schering Pharma AG, Berlin, Germany) with advantages in both MRA and in the differential diagnosis of tumors, particularly in perfusion studies of the myocardium and potential in MR lung perfusion. Dozens of the relatively small molecule Gd-DTPA is bound covalently to polylysine, a large molecular weight backbone. The stable, highly water-soluble agent does not diffuse through the endothelium of the vascular system; it is subject to renal elimination.

The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology and Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.

MRI Contrast Agents: